New Low-Light Level Therapy Shows Promising Results for CCCA

REVIAN Inc. revealed positive outcomes for the use of REVIAN Red System to treat patients with Central Centrifugal Cicatricial Alopecia (CCCA).¹ Researchers at Wake Forest University School of Medicine in Salem-West, North Carolina, presented their findings regarding CCCA and the REVIAN Red System at the virtual 2021 Society for Investigative Dermatology annual meeting.